Indivior(INDV)
Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
Mock data
Subscribe for the real data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Buprenex | Buprenorphine | 1982-01-01 | 2024-2038 | |
| Perseris | Risperidone | 2018-07-27 | 2025-2033 | |
| Sublocade | Buprenorphine | 2017-11-30 | 2024-2038 | |
| Suboxone | Buprenorphine, Naloxone | 2002-10-08 | 2024-2038 | |
| Subutex | Buprenorphine | 2002-10-08 | 2024-2038 | |
| Opvee | Nalmefene | 2023-05-22 | 2038 |
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use